Are complement cascade activation thresholds genetically calibrated differently across SEA versus other populations in AD?

OPEN

The hypothesis proposed ancestry-specific complement system responses but the skeptic noted zero direct evidence exists. This knowledge gap prevents understanding whether neuroinflammatory therapeutic targets need population-specific calibration. Source: Debate session sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222549-20260402 (Analysis: SDA-2026-04-04-gap-debate-20260403-222549-20260402)

Priority: 0.70 Domain: neuroinflammation Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Are complement cascade activation thresholds genetically calibrated differently across SEA versus other populations in AD? is a 0.7 priority gap in neuroinflammation. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Are complement cascade activation thresholds genetically calibrated differently across SEA versus other populations in AD? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (1)

NRF2→Are

associated with (20)

entities-histone-methylation→ADentities-atp7b-gene→ADentities-ros→ADTAU→ADTDP-43→AD
▸ Show 15 more

biomarker for (1)

tau cleavage products→AD

causes (6)

AD→neurodegenerationBETA_AMYLOID→ADAD→IMMUNE_TOLAD→memory_lossAD→DEMENTIA
▸ Show 1 more

component of (1)

NFE2L2→Are

cross disease mechanism in (5)

MAPT→ADTREM2→ADNLRP3→ADPINK1→ADGRN→AD

depleted in (1)

SPM_levels→AD

prevents (1)

NAD+ augmentation→AD

protective against (1)

cognitive stimulation→AD

regulates (2)

Are→Inflammatory MediatorsAD→PROTEOME

risk factor for (4)

APOE ε4→ADgenetically at-risk individuals→ADAPOE4→ADmicroglial priming→AD

targets (1)

resveratrol→AD

therapeutic target for (6)

TREM2→ADCCR2→ADlevetiracetam→ADSaracatinib→ADanti-amyloid antibodies→AD
▸ Show 1 more
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps